Replies to post #524998 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Not sure what you are disagreeing with. The post I responded to wasn't certain on those things either.

Have a good one Flipper.

[GermanCol]

We don't know, but we can estimate and theorize. Time will tell which theories were close to reality and which ones where not.

Also, Dr. Bosch said:

Actually, the number of IDH mutations was, I think, seven patients out of 331, which is lower than what you saw in the comparator groups

If we look at the results presentation, what he said wasn’t right. That's maybe why he said "I think" and he didn't assure that.

It was wrong because actually the 7 IDH-1 mutated where not from the 331 ITT population, but from the 232 nGBM arm:

232 * 3% = 6.96.

See the 3% below in yellow:



Also, there were 2 more IDH1 mutated patients in the rGBM treatment arm:

3% x 64 = 1.92.

See the 3% below in yellow:



So we have at least 9 IDH1 mutated patients in the trial, plus the ones in the 35 group, which I think are going to be present in a higher percentage than 3% because of the reasons I explained in previous posts.